Skip to content
Credit reportVerdict and grounds
Made on 22-11-2026 at 19:58
Reference CK-0678830942-20261122

CODEMA PHARMA

ActivePublic limited company0678.830.942Robert Schumanplein 2-4, 1040 Brussels
Retail sale of pharmaceutical products (NACE 47730) · founded in 2017 · one director · accounts in the micro format

Sources: the KBO register on 22-11-2026; the National Bank, 2025 annual accounts filed on 31-08-2026; the Belgian Official Gazette, latest deed of 17-03-2026.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,399 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
-€34,489
-€8,983 in 2024
Net result
-€32,963
-€9,231 in 2024
Equity
€71,289
▼ 31.6% against 2024
Cash
€2,366
▲ 44.4% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, CODEMA PHARMA made a loss of €32,963.Annual accounts 2025 page 2
  2. Equity stands at €71,289, or 19.0% of the balance sheet total of €375,959. The solvency of 19.0% is higher than at 38% of the 25,459 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
  3. The 2025 accounts reached the National Bank on 31-08-2026, 31 days after the term.National Bank, filing of 31-08-2026 page 4

Representation

Two directors jointly represent CODEMA PHARMA. The sole director is .

Articles of association, Belgian Official Gazette of 27-07-2017, deed 17317541

Ownership

The accounts in the micro format list no shareholders. holds 825 shares. There are 2 other shareholders.

Deed of 27-07-2017

CODEMA PHARMA · 0678.830.942 · credit report of 22-11-2026Page 1 of 5
CODEMA PHARMA0678.830.942 · report of 22-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin euro

2021-45,4172022-38,4412023399,8032024-8,9832025-34,4892021-77,6932022-55,9092023400,6702024-9,2312025-32,963
gross marginnet result

Equity and debtsin euro

2021202220232024202571,289304,670
equitydebts

Cashin euro

20213,61020221,63520231,58020241,63920252,366
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin-€45,417-€38,441€399,803-€8,983-€34,489
Operating result-€77,498-€54,805€399,803-€8,983-€34,489
Net result-€77,693-€55,909€400,670-€9,231-€32,963
Balance sheet at the closing date
Equity-€231,278-€287,186€113,483€104,252€71,289
Debts€302,600€339,508€297,786€305,645€304,670
Debts due after more than one year€10,000----
Debts due within one year€290,932€337,841€296,118€303,977€304,670
Cash€3,610€1,635€1,580€1,639€2,366
Balance sheet total€71,322€52,322€411,269€409,897€375,959
Ratios
Solvency-324.3%-548.9%27.6%25.4%19.0%
Liquidity0.190.151.391.351.23

Source: Annual accounts 2025, micro format, filed on 31-08-2026 (2026-00497957); Annual accounts 2024, micro format, filed on 14-07-2025 (2025-00272048); Annual accounts 2021 to 2023, filed from 26-07-2022 to 24-07-2024 (2022-20232836, 2023-00267667, 2024-00285604).

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

CODEMA PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from -€8,983 to -€34,489.

CODEMA PHARMA · 0678.830.942 · credit report of 22-11-2026Page 2 of 5
CODEMA PHARMA0678.830.942 · report of 22-11-2026

Board, signature and ownership

Position on 22-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

Two directors jointly represent CODEMA PHARMA. The sole director is .

Articles of association, Belgian Official Gazette of 27-07-2017, deed 17317541

Board

one director in office
Directorsince 30-06-2020
deed of 19-06-2023

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds 825 shares. holds 825 shares. holds 14,850 shares.

Deed of 27-07-2017

Board changes

and resign. appointed. General meeting of 07-06-2023.

Gazette, deed 23079177

resigns as director. appointed as director. General meeting of 06-04-2018.

Gazette, deed 18070666
CODEMA PHARMA · 0678.830.942 · credit report of 22-11-2026Page 3 of 5
CODEMA PHARMA0678.830.942 · report of 22-11-2026

Events and comparison

The last 24 months, newest first

Annual accounts 2025 filed, 31 days late.

NBB filing

Registered office moved from Woluwe St Lambert to Brussels. The registered office moved from Clos Chapelle aux Champs 30, 1200 Woluwe St Lambert to Rond-Point Schuman 2-4 (Levels 5 & 6, EU Quarter) à 1040 Bruxelles.

Gazette, deed 26038269

Address struck.

KBO administration

Annual accounts 2024 filed, 17 days before the deadline.

NBB filing

Comparable companies, two years later

In July 2024, 1,546 companies had the same profile as CODEMA PHARMA has now: micro, 5 to 10 years old, solvency 10 to 30% and a small loss. Two years later 91.3% were still trading, 4.3% had stopped another way and 4.3% had gone bankrupt.

still trading 91.3% stopped another way 4.3% bankrupt 4.3%

The return on assets of CODEMA PHARMA, -8.8%, is higher than at 19% of the 24,646 companies filing micro accounts in retail trade (NACE 47) in 2025.

Other findings

Peppol

Not listed in the Peppol Directory.

Sanctions lists

CODEMA PHARMA · 0678.830.942 · credit report of 22-11-2026Page 4 of 5
CODEMA PHARMA0678.830.942 · report of 22-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units22-11-2026KBO 0678.830.942
National Bank of BelgiumAnnual accounts 2025, micro format31-08-20262026-00497957
National Bank of BelgiumAnnual accounts 2024, micro format14-07-20252025-00272048
National Bank of BelgiumAnnual accounts 2021 to 202326-07-2022 to 24-07-20242022-20232836, 2023-00267667, 2024-00285604
Belgian Official GazetteBoard19-06-2023deed 23079177
Belgian Official GazetteBoard02-05-2018deed 18070666
Belgian Official GazetteArticles of association with the signing rule27-07-2017deed 17317541
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies21-11-2026bankruptcy model of 21 November 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 21 November 2026, computed on 21-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

CODEMA PHARMA · 0678.830.942 · credit report of 22-11-2026Page 5 of 5